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For primary radiation therapy (RT) of prostate cancer, dose intensification is established 
as standard of care. Less is known on the role of dose intensification in the postprosta-
tectomy setting for salvage RT. Thus, we aimed to identify and summarize the existing 
literature. In retrospective analyses, dose-intensified salvage RT showed a superior bio-
chemical control compared to standard dose salvage radiation with favorable acute and 
late gastrointestinal and genitourinary toxicity rates, especially when modern radiation 
techniques such as intensity modulated RT were applied. We identified one randomized 
phase III trial addressing the potential benefits of dose-intensified salvage RT (SAKK 
09/10). Recently, acute gastrointestinal and genitourinary toxicities and early quality of life 
data of this trial were reported, and no significant difference in acute toxicities between 
both treatment arms were found; however, a significant worsening of genitourinary 
quality of life was noted in the dose-intensified treatment arm. Whereas dose-intensified 
salvage RT appears to be feasible and well tolerated, the improved biochemical control 
rates using dose intensified RT as suggested by retrospective analyses have yet to be 
validated by prospective trials.
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iNTRODUCTiON
Around 30,000 men will experience recurrence of prostate cancer after radical prostatectomy 
annually in the United States (1). For the majority of these patients, the only evidence of recurrent 
disease is an increasing serum PSA level without evidence of macroscopic recurrence. After radi-
cal prostatectomy approximately 15–40% of men develop a biochemical relapse within 5 years (2, 
3). It has been described that the site of relapse in prostate cancer patients after prostatectomy is 
predominantly local, with a relatively low incidence of distant failures (4). Patients with biochemical 
relapse develop bone metastasis with a rate of 37 and 65% at 5 and 10 years, respectively. A median 
time of 8 years until development of bone metastasis was reported and the observed median time 
between the development of bone metastasis and death was 5 years (5).
Generally, two main strategies are being used to increase long-term tumor control after prostatec-
tomy: either adjuvant radiation therapy (RT) in the presence of positive surgical margins, extracap-
sular extension or seminal vesicle invasion, or salvage RT at biochemical relapse. The advantages of 
dose intensification in primary prostate cancer were already shown in several randomized controlled 
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trials. The meta-analysis by Viani et al. reported a reduction of 
biochemical relapse rates after dose intensified RT vs. conven-
tional dose RT. However, the dose intensification was associated 
with increasing rates of grade 2 or higher gastrointestinal toxicity 
(6).
For the postprostatectomy setting, retrospective analyses 
have demonstrated the effectiveness of salvage RT in terms of 
biochemical relapse-free survival and cancer-specific survival (7, 
8), and thus salvage RT is considered the only potentially cura-
tive treatment at the earliest sign of biochemical failure. Further 
analyses showed that dose-intensified salvage RT achieved 
superior biochemical relapse-free survival compared to standard 
doses (9–11).
As standard for salvage RT, a dose of 64–66 Gy is recommended 
in the guidelines of the European Association of Urology (EAU) 
at PSA serum levels of ≤0.5 ng/ml (12). The American Society 
of Radiation Oncology (ASTRO) guidelines recommend using 
the highest RT dose deliverable with acceptable toxicity rates and 
suggest a minimum dose of 64–65  Gy with conventional dose 
fractionation (13).
Less is known regarding dose intensification in the salvage RT 
setting. We have thus reviewed and summarized the literature for 
dose-intensified salvage RT.
MATeRiALS AND MeTHODS
Data for this Review were identified by non-systematic searches 
of MEDLINE, Current Contents, PubMed, and references 
from relevant articles using medical subject headings including 
“prostate cancer,” “postoperative,” “radiotherapy,” “radiation,” 




King et al. described improved biochemical relapse-free survival 
rates for dose-intensified salvage RT (70 Gy) compared to doses 
of 60 Gy. One hundred twenty-two patients were treated either 
with a dose of 60  Gy (n =  38) or 70  Gy (n =  84) using two-
dimensional (2D) conformal, three-dimensional (3D) conformal, 
or intensity modulated RT (IMRT) between 1984 and 2004. 
Sixty-eight patients received additional androgen deprivation 
therapy (ADT). The median follow up was >5 years, and patients 
with 70 Gy treatment had a biochemical relapse-free survival of 
58 vs. 25% when treated with 60 Gy. In a multivariate analysis, 
higher dose was an independent factor for superior biochemical 
relapse-free survival (9).
Likewise, Ost et  al. evaluated 136 patients who received a 
salvage IMRT with a median dose of 76  Gy alone (n =  39) or 
combined with ADT (n = 97) between 1999 and 2008. After a 
median follow up of 5 years, a biochemical relapse-free survival 
of 56% and a clinical relapse-free survival of 86% were observed 
(14). Moreover, Goenka et  al. published a retrospective study 
analyzing 285 salvage RT patients, 72% were treated with a RT 
dose ≥70  Gy using either 3D or IMRT techniques. Thirty-one 
percent received additional ADT. The median follow up was 
60 months. After 7 years, biochemical relapse-free survival was 
37% and distant metastases-free survival was 77% (15). Moreover, 
a systematic review with regression meta-analysis and radiobio-
logical modeling performed by Ohri et  al. analyzed 25 studies 
with 3,828 patients with a median follow up of 50 month. The 
RT dose ranged from 60 to 72 Gy (median dose: 65 Gy) and 2D, 
3D, or IMRT techniques were applied. The authors observed a 
median 5-year biochemical relapse-free survival of 47% and 
detected a dose-related increase of 5-year biochemical relapse-
free survival. Each increase of 1 Gy led to an increase of 2.5% 
of 5-year biochemical relapse-free survival rates (10). Another 
systematic review published by King analyzed 41 studies with 
5,597 patients. The median follow up was 47 ± 22 months, and the 
applied median dose was 64.6 ± 3.1 Gy. King reported a median 
relapse-free survival of 34% when RT dose was 60 Gy and 54% 
with an applied dose of 70 Gy. For each additional 1 Gy, a 2% 
improvement of relapse-free survival was estimated (16).
The systematic review by Ohri et al. also analyzed the dose-
dependent toxicity of 3,828 salvage RT patients treated with 
2D/3D or IMRT techniques with a median dose of 65 Gy. A toxic-
ity model was generated and showed increasing dose-dependent 
rates of ≥grade 3 genitourinary and gastrointestinal toxicity. The 
authors estimated that with each dose increase of 1 Gy, the rate 
of ≥grade 3 gastrointestinal late toxicity would increase about 
1.2% and grade 3 genitourinary late toxicity rates would increase 
0.8%. Furthermore, it was assumed that a rate of >10% late grade 
3 gastrointestinal and genitourinary side effects would occur 
when RT dose exceeds 72 Gy (10). One important limitation of 
this toxicity model was, however, its dependency on series with 
2D/3D treatment techniques. Moreover, the applied doses in the 
analyzed series were ≤70  Gy. So this model may not be valid 
to estimate toxicity rates for more modern RT approaches and 
application of doses >70 Gy (17).
Cozzarini et  al. described the long-term toxicity rates of 
742 patients treated between 1993 and 2005 with adjuvant RT 
or salvage RT using 2D and 3D conformal techniques (median 
follow up 8 years). The salvage RT (n = 186) with a median dose 
of 72 Gy resulted in ≥grade 2 late genitourinary toxicity in 23.7% 
of the patients. Grade 3 late genitourinary toxicity occurred in 
10% of the patients. Grade 2 or higher acute toxicity and a dose 
of >72 Gy were identified as independent prognostic factors for 
late grade 3 genitourinary toxicity (18).
Goenka et al. evaluated toxicity rates of 285 patients treated 
between 1988 and 2007 with salvage RT (median follow up 
60 months). One hundred nine patients who received 3D confor-
mal RT (n = 12: <66 Gy; n = 57: 66 to <70 Gy; n = 40: ≥70 Gy) 
were compared to 176 patients who underwent IMRT (n =  3: 
<66 Gy; n = 8: 66 to <70 Gy; n = 165: ≥70 Gy). A 8.3% reduc-
tion of late ≥grade 2 gastrointestinal toxicity was reported using 
IMRT (toxicity rate: 1.9%) compared to 3D conformal RT (toxic-
ity rate: 10.2%). In this series, no acute grade 3 gastrointestinal 
toxicity and only 1.4% late grade 3 gastrointestinal toxicity were 
observed. The overall ≥grade 2 late genitourinary toxicity rate 
was 16.3% with no significant difference between the different 
RT techniques (15, 19). Similar low grade 3 late gastrointestinal 
toxicity rates were reported by Ost et al. (grade 3 gastrointestinal 
March 2016 | Volume 6 | Article 483
Beck et al. Dose-Intensified Salvage Radiation Therapy
Frontiers in Oncology | www.frontiersin.org
toxicity <1%) using IMRT (mean dose: 76 Gy) for salvage RT of 
136 patients. Late genitourinary ≥grade 2 toxicity rates were 22%, 
and the grade 3 late genitourinary toxicity rate was 3% (14).
Prospective Randomized Data
Only one randomized prospective phase III trial testing dose-
intensified salvage RT was identified (conducted by the Swiss 
Group for Clinical Cancer Research, SAKK). The SAKK 09/10 
trial was closed for accrual after it met its accrual goal of 350 
patients (2011–2014). In this trial, salvage RT with 70  Gy was 
compared to a dose of 64  Gy. A recent analysis of this trial 
reported acute toxicity rates and early quality of life in 344 
patients being eligible in the safety population (20). European 
Organization for Research and Treatment of Cancer (EORTC) 
delineation guidelines were used (21), and toxicity was scored 
according to National Cancer Institute Common Terminology 
Criteria for Adverse events (CTC AE, version 4.0). Quality of life 
was analyzed with the EORTC Quality of Life Questionnaires 
C30 and PR25. Acute grade 2 genitourinary toxicity occurred in 
13%, grade 3 genitourinary toxicity in 0.6% treated with 64 Gy 
compared to 16.6 and 1.7% grade 2 and 3 genitourinary toxicity 
after 70 Gy, respectively. Acute grade 2 gastrointestinal toxicity 
occurred in 16%, grade 3 gastrointestinal toxicity in 0.6% treated 
with 64  Gy compared to 15.4 and 2.3% acute grade 2 and 3 
gastrointestinal toxicity after 70  Gy, respectively. There was no 
significant difference in acute toxicity rates (CTC AE based) 
between both arms. Generally, changes in health related quality of 
life were minor; however, there was a more pronounced and clini-
cally relevant worsening of genitourinary symptoms in the 70 Gy 
arm. Thus, the initial results of SAKK 09/10 trial confirmed low 
acute toxicity rates even after dose intensified RT of up to 70 Gy, 
whereas only slight but significant increase in patient reported 
early urinary symptoms was shown. In 44% of the patients, the 
RT was applied using a 3D-conformal approach and in 56% of the 
patients using an IMRT/rotational RT approach (RT technique 
was a stratification factor). There was no significant difference 
in acute gastrointestinal or genitourinary toxicity associated 
with RT technique (20). The first randomized prospective data 
regarding freedom from biochemical recurrence (primary trial 
endpoint) and late toxicity after dose-intensified salvage RT are 
awaited in 2017.
DiSCUSSiON
Retrospective analyses showed improved biochemical control 
rates after dose-intensified salvage RT with a dose-dependent 
increase of biochemical relapse-free survival (9–11). The avail-
able data suggested slightly increased toxicity rates for dose-
intensified salvage RT, when compared to standard dose salvage 
RT, but both gastrointestinal and genitourinary toxicity rates are 
generally favorably, even after dose-intensified salvage RT (14, 15, 
18, 19).
These findings are confirmed by recent published data from 
the randomized SAKK 09/10 prospective trial, where low rates 
of grade 2 and 3 gastrointestinal and genitourinary acute toxic-
ity were described without a significant difference between the 
two trial arms (total dose 64 vs. 70 Gy). However, there was a 
significant worsening of genitourinary early quality of life after 
treatment with 70 Gy. Therefore, some caution might be directed 
toward impairment of genitourinary early quality of life, which 
has to be weighed up against potential improvements in bio-
chemical control (20). It was assumed that the necessity to include 
the bladder neck and the vesico-urethral anastomosis in the high 
dose salvage RT volume would result in similar genitourinary 
toxicity regardless of RT technique (17). A worsening of urinary 
symptoms after high dose RT to urethra, bladder neck, and blad-
der trigonum was also described in the primary prostate cancer 
RT (22). This might be the reason for the observed significant 
worsening of patient who reported urinary symptom burden in 
the quality of life analysis of SAKK 09/10 (20). It has been well 
described that patient-reported toxicity scoring systems are more 
reliable and more sensitive as compared to physician-reported 
toxicity scoring systems (23), which might be the reason that 
there was no significant difference in the acute CTC AE-based 
toxicity scores between the two trial arms.
Interestingly, the SAKK 09/10 trial did stratify for RT tech-
nique (3D-conformal RT vs. IMRT/rotational techniques). 
However, no association was found between RT technique and 
acute toxicity or early quality of life. This is in contrast to several 
retrospective analyses that reported that IMRT was associated 
with a reduced rate of gastrointestinal toxicity as compared to 
3D conformal RT in the setting of dose-intensified salvage RT 
(without a significant difference in genitourinary toxicity) (14, 15, 
19). Interestingly, despite being based on retrospective data only, 
a survey asking physicians in the United States for implemented 
techniques showed that a majority used IMRT for the salvage 
RT setting (24). However, in the primary RT setting of prostate 
cancer (using a higher total dose), preliminary results of the 
prospective randomized RTOG 0126 trial showed significantly 
reduced gastrointestinal and genitourinary acute toxicity rates 
using IMRT compared to 3D conformal RT (25).
In this context, it is important to consider different delinea-
tion guidelines with obviously different target volume sizes and 
its implication for clinical practice. For example, the SAKK 09/10 
trial used the EORTC delineation guidelines for clinical (CTV) 
and planning (PTV) target volumes (20, 21) that were described 
to be significantly smaller compared to other recommendations 
such as the Faculty of Radiation Oncology Genito-Urinary Group 
(FROGG), the Princess Margaret Hospital (PMH), and the RTOG 
guidelines (26). Hence, the toxicity rates observed in SAKK 09/10 
trial and maybe also the differences between the two dose levels 
in terms of toxicity results could potentially be higher if other 
delineation guidelines were used.
Otherwise, recently published data confirm that there are 
other promising treatment options to improve the efficacy of sal-
vage RT. The use of ADT as an additional treatment in the salvage 
setting was analyzed by two randomized phase III studies. The 
GETUG-AFU 16 trial compared standard dose salvage RT (66 Gy) 
alone vs. salvage RT combined with short-term ADT (66 Gy plus 
6-month goserelin) and detected a significant improvement in 
5-year progression-free survival for the combined treatment. 
More acute toxicities (<grade 3) were observed after combined 
treatment but acute grade 3 or late toxicity was not significantly 
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different between the trial arms (27). Moreover, the long-term 
results of RTOG 9601, a trial that compared standard dose salvage 
RT (64.8 Gy) vs. salvage RT with long-term ADT (64.8 Gy plus 
24-month bicalutamide), showed a significant overall survival 
benefit after 10  years with 78% for RT alone vs. 82% for the 
combined treatment (hazard ratio 0.75, 95% CI: 0.58–0.98). No 
significant difference in grade 3 or 4 late toxicity was described, 
whereas significantly more gynecomastia was observed in the 
bicalutamide group (70%) vs. RT (11%) (28). However, both 
studies applied a standard dose RT, and thus no firm conclusions 
about combination of ADT with dose-intensified salvage RT 
can be made and whether this would lead to a similar or better 
outcome or to unacceptable toxicity. Thus, it has to be considered 
that ADT is associated with multiple short and long-term side 
effects like bone loss, sexual dysfunction, hot flashes, metabolic 
changes, fatigue, gynecomastia among others (29). It might be 
that dose-intensified salvage RT alone achieves similar results 
without ADT-associated side effects or at least might be capable 
to significantly delay the use of ADT. Another potential option to 
achieve improved outcome in the salvage RT is regional hyper-
thermia, which will be investigated in a novel phase II trial (30).
Finally, until biochemical relapse-free survival and late 
toxicity rates from the SAKK 09/10 trial become available, the 
described worsening of genitourinary quality of life after 70 Gy 
must be weighted up against benefits in cancer control, poten-
tially being obtained by dose intensification. For patients without 
macroscopic recurrence, one practical solution could be to 
deliver dose-intensified salvage RT up to 70–72 Gy in the absence 
of acute genitourinary toxicity but to stop the salvage RT after 
66 Gy in the presence of significant acute toxicity. Alternatively, a 
simultaneous integrated boost technique (SIB) might be applied 
to selectively apply a higher dose to the high-risk quadrant of 
the prostatic bed (e.g., pT3, R1) while sparing the vesico-urethral 
anastomosis/urethra if possible. Patients with macroscopic recur-
rences will probably benefit from higher doses (toward 76 Gy) 
and the addition of ADT.
CONCLUSiON
According to retrospective data, dose-intensified salvage RT 
appears to be well tolerated and effective. However, a slight 
increase in acute and late toxicities using dose-intensified sal-
vage radiation treatment could be detected. A prospective trial 
reported favorable acute toxicity rates after dose-intensified 
salvage RT, but biochemical control rates and late toxicity data of 
this trial are still pending. As long as these prospective data are 
not available, the potential benefits in biochemical control and 
the mild increase of toxicities in dose-intensified salvage RT (both 
reported in retrospective studies) have to be weighed up.
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